Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis

作者：Tidswell Mark^*; LaRosa Steven P

来源：Expert Review of Anti-Infective Therapy, 2011, 9(5): 507-520.

DOI：10.1586/ERI.11.27

• E5564
• endotoxin
• eritoran tetrasodium
• sepsis
• severe sepsis
• TLR-4

The human innate immune system initiates inflammation in response to bacterial molecules, particularly Gram-negative bacterial endotoxin. The steps by which endotoxin exposure leads to systemic inflammation include binding to Toll-like receptor-4 that specifically recognizes endotoxin and subsequently triggers cellular and molecular inflammatory responses. Severe sepsis is a systemic inflammatory response to infection that induces organ dysfunction and threatens a person's survival. Severe sepsis is frequently associated with increased blood levels of endotoxin. It is a significant medical problem that effects approximately 700,000 patients every year in the USA, resulting in 250,000 deaths. Eritoran tetrasodium is a nonpathogenic analog of bacterial endotoxin that antagonizes inflammatory signaling by the immune receptor Toll-like receptor-4. Eritoran is being evaluated for the treatment of patients with severe sepsis.

• 出版日期2011-5